High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort
Copyright © 2023 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved..
BACKGROUND AND AIMS: The upper limits of normal serum uric acid (SUA) or the lower limits of hyperuricemia were frequently set at 420 or 360 μmol/L (7.0 or 6.0 mg/dL). We aimed to explore the association between high-normal SUA (360 ≤ SUA≤420 μmol/L) and incidence of macrovascular and renal events based on a 10-year cohort with type 2 diabetes mellitus (T2DM) to explore which cut-off was more appropriate.
METHODS AND RESULTS: A total of 2988 patients with T2DM without hyperuricemia (SUA≤420 μmol/L) were included and followed up. Cox proportional hazards models and restricted cubic spline regression were used to evaluate the relationship between baseline SUA (as continuous and categorical variable) and macrovascular and renal events. Patients were grouped as low-normal (SUA<360 μmol/L) and high-normal groups based on baseline SUA, and the latter group had higher incidence of macrovascular events. Multivariate Cox regression analysis indicated that baseline levels of SUA were significantly associated with cardiovascular (HR = 1.385, 95%CI:1.190-1.613, P < 0.001) and peripheral vascular events (HR = 1.266, 95%CI:1.018-1.574, P = 0.034), and the linear association existed. Moreover, fully adjusted multivariable Cox analyses indicated high-normal SUA increased the risks of cardiovascular (HR = 1.835, 95%CI:1.319-2.554, P < 0.001) and peripheral vascular events (HR = 1.661, 95%CI:1.000-2.760, P = 0.050) compared to low-normal SUA.
CONCLUSIONS: Baseline SUA levels were positively associated with cardiovascular and peripheral vascular events, and high-normal SUA increased the risks of these events in patients with T2DM even without hyperuricemia. A threshold value for SUA of 360 μmol/L should be more appropriate in terms of predicting macrovascular events risks compared to the value of 420 μmol/L.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Nutrition, metabolism, and cardiovascular diseases : NMCD - 33(2023), 10 vom: 12. Okt., Seite 1989-1997 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Chifa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
268B43MJ25 |
|---|
| Anmerkungen: |
Date Completed 20.09.2023 Date Revised 03.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.numecd.2023.07.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360739199 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360739199 | ||
| 003 | DE-627 | ||
| 005 | 20231226083643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.numecd.2023.07.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360739199 | ||
| 035 | |a (NLM)37574432 | ||
| 035 | |a (PII)S0939-4753(23)00281-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Chifa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2023 | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: The upper limits of normal serum uric acid (SUA) or the lower limits of hyperuricemia were frequently set at 420 or 360 μmol/L (7.0 or 6.0 mg/dL). We aimed to explore the association between high-normal SUA (360 ≤ SUA≤420 μmol/L) and incidence of macrovascular and renal events based on a 10-year cohort with type 2 diabetes mellitus (T2DM) to explore which cut-off was more appropriate | ||
| 520 | |a METHODS AND RESULTS: A total of 2988 patients with T2DM without hyperuricemia (SUA≤420 μmol/L) were included and followed up. Cox proportional hazards models and restricted cubic spline regression were used to evaluate the relationship between baseline SUA (as continuous and categorical variable) and macrovascular and renal events. Patients were grouped as low-normal (SUA<360 μmol/L) and high-normal groups based on baseline SUA, and the latter group had higher incidence of macrovascular events. Multivariate Cox regression analysis indicated that baseline levels of SUA were significantly associated with cardiovascular (HR = 1.385, 95%CI:1.190-1.613, P < 0.001) and peripheral vascular events (HR = 1.266, 95%CI:1.018-1.574, P = 0.034), and the linear association existed. Moreover, fully adjusted multivariable Cox analyses indicated high-normal SUA increased the risks of cardiovascular (HR = 1.835, 95%CI:1.319-2.554, P < 0.001) and peripheral vascular events (HR = 1.661, 95%CI:1.000-2.760, P = 0.050) compared to low-normal SUA | ||
| 520 | |a CONCLUSIONS: Baseline SUA levels were positively associated with cardiovascular and peripheral vascular events, and high-normal SUA increased the risks of these events in patients with T2DM even without hyperuricemia. A threshold value for SUA of 360 μmol/L should be more appropriate in terms of predicting macrovascular events risks compared to the value of 420 μmol/L | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Atherosclerotic cardiovascular disease | |
| 650 | 4 | |a Diabetic macrovascular events | |
| 650 | 4 | |a High-normal serum uric acid | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 700 | 1 | |a Yu, Hengchi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Weinan |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Hanjing |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Guangran |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xuelian |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Rongrong |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Yujie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jiandong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuling |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yingjun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Liangxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Shenyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Mingxia |e verfasserin |4 aut | |
| 700 | 0 | |a of Beijing Community Diabetes Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Jianping |e investigator |4 oth | |
| 700 | 1 | |a Pan, Sufang |e investigator |4 oth | |
| 700 | 1 | |a Ji, Yu |e investigator |4 oth | |
| 700 | 1 | |a Gao, Dayong |e investigator |4 oth | |
| 700 | 1 | |a Cui, Xueli |e investigator |4 oth | |
| 700 | 1 | |a Wang, Ziming |e investigator |4 oth | |
| 700 | 1 | |a Dai, Qinfang |e investigator |4 oth | |
| 700 | 1 | |a Li, Yue |e investigator |4 oth | |
| 700 | 1 | |a Liu, Deyuan |e investigator |4 oth | |
| 700 | 1 | |a Yang, Xiujuan |e investigator |4 oth | |
| 700 | 1 | |a Cheng, Shuyan |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Nan |e investigator |4 oth | |
| 700 | 1 | |a Xu, Shiqian |e investigator |4 oth | |
| 700 | 1 | |a Gao, Ying |e investigator |4 oth | |
| 700 | 1 | |a Li, Yongjin |e investigator |4 oth | |
| 700 | 1 | |a Xu, Jing |e investigator |4 oth | |
| 700 | 1 | |a Wu, Hao |e investigator |4 oth | |
| 700 | 1 | |a Miao, Jie |e investigator |4 oth | |
| 700 | 1 | |a Wang, Qian |e investigator |4 oth | |
| 700 | 1 | |a Chen, Yujie |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Li |e investigator |4 oth | |
| 700 | 1 | |a Lu, Zongxue |e investigator |4 oth | |
| 700 | 1 | |a Ma, Shuxian |e investigator |4 oth | |
| 700 | 1 | |a Yang, Shuqin |e investigator |4 oth | |
| 700 | 1 | |a Bai, Wei |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nutrition, metabolism, and cardiovascular diseases : NMCD |d 1997 |g 33(2023), 10 vom: 12. Okt., Seite 1989-1997 |w (DE-627)NLM090675177 |x 1590-3729 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:10 |g day:12 |g month:10 |g pages:1989-1997 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.numecd.2023.07.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 10 |b 12 |c 10 |h 1989-1997 | ||